NCT00828919 2024-12-03
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Pfizer
Phase NA Completed
Clinical Trials
5 trialsNCT02164838 2018-01-29
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT01211275 2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT01469052 2012-03-26
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00949624 2012-01-19
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Arog Pharmaceuticals, Inc.
Phase 1 Completed